acellular pertussis vaccine

acellular pertussis vaccine

n. Abbr. DTaP
A diphtheria, tetanus, pertussis vaccine containing two or more antigens but no whole cells.
References in periodicals archive ?
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.
He was senior coauthor of a recent study that addresses why acellular pertussis vaccine immunity wanes so quickly.
Contract notice: Equivalent to a vaccine against diphtheria, tetanus and acellular pertussis vaccine containing pertussis component to the vaccination of children 6 years of age.
A single dose of Quadracel vaccine is approved for use in children four through six years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received four doses of Pentacel and/or DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), stated the company.
Some of our current vaccines don't work as well as we could hope, including the acellular pertussis vaccine, as Dr.
Furthermore, the duration of protection afforded by the newer acellular pertussis vaccine (1-3 years) is shorter than that for the whole-cell vaccine (5-10 years).
The acellular pertussis vaccine is more purified and uses only selected portions of the pertussis bacteria to stimulate an immune response.
Studies have suggested that protection following the acellular pertussis vaccine is less enduring than following the whole-cell pertussis vaccine," said lead study author Nicola Klein, MD, PhD, of the Kaiser Permanente Vaccine Study Center.
For example, the older whole cell pertussis vaccine causes the production of about 3000 different antibodies, whereas the newer acellular pertussis vaccine causes the production of 6 or fewer different antibodies.
Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.
Pertussis toxin (PT) is the main component of current acellular pertussis vaccine and the 51 (subunit1) is the main immunogenic part of it.
The Study: Studies have shown that newborns immunized with acellular pertussis vaccine (aPV) develop immunity.